(a) (i) Name the clinical tests for checking sapheno-femoral junction competence and deep venous system patency. (ii) Enumerate…

Varicose Veins and Venous Ulcer Management

Clinical Tests: Sapheno-femoral junction (SFJ) competence is evaluated using the Brodie-Trendelenburg test (Part I), where a tourniquet is applied to the upper thigh with the leg elevated and emptied; rapid filling from above upon release indicates SFJ incompetence. Other tests include the Morrissey cough impulse test and Schwartz test. Deep venous system patency is evaluated using Perthes test and the Modified Perthes test (applying a tourniquet below the knee and asking the patient to walk; decompression of superficial veins confirms a patent deep venous system and competent perforators).

Complications of Varicose Veins: Chronic venous hypertension leads to cutaneous and vascular complications:

1. Venous stasis dermatitis (stasis eczema) and pruritus.
2. Hemosiderin pigmentation and lipodermatosclerosis (inverted champagne-bottle leg appearance).
3. Atrophie blanche and venous ulceration, classically situated in the gaiter zone (medial malleolus).
4. Superficial thrombophlebitis.
5. Hemorrhage (external rupture of thin-walled varices, which can be profuse).
6. Periostitis of the underlying tibia and secondary Marjolin's ulcer (malignant degeneration in long-standing non-healing ulcers).

Management of Venous Ulcer: Assessment requires Duplex ultrasonography to map venous reflux and deep patency, along with Ankle-Brachial Index (ABI) to rule out concurrent arterial insufficiency (ABI must be >0.8 for high-compression therapy).

1. Compression Therapy: This is the cornerstone of conservative management. Four-layer bandaging or short-stretch multicomponent compression bandages provide a pressure of 30–40 mmHg at the ankle, counteracting venous hypertension.
2. Limb Elevation and Mobility: Elevating the legs above the level of the heart during rest and structured calf-muscle exercises to enhance the calf muscle pump.
3. Local Wound Care: Sharp or autolytic debridement of necrotic tissue, infection control, and non-adherent moist dressings.
4. Pharmacotherapy: Oral Pentoxifylline (400 mg thrice daily) or micronized purified flavonoid fractions (MPFF) to improve microvascular perfusion.
5. Surgical/Endovenous Correction: Superficial venous ablation (Endovenous Laser Ablation, Radiofrequency Ablation, or SFJ flush ligation with stripping) to eliminate reflux. Large refractory ulcers may require split-thickness skin grafting (SSG).

---

Acute Retention of Urine and Benign Prostatic Hyperplasia

Management of Acute Retention: The immediate objective is rapid and safe decompression of the urinary bladder:

1. Urethral Catheterization: Perform immediate urethral catheterization under strict aseptic conditions using a 14–16 Fr Foley catheter with abundant lubricating lidocaine gel. Decompress the bladder completely.
2. Failed Catheterization: If resistance is encountered (due to an enlarged median lobe, false passage, or stricture), force must not be applied. An emergency percutaneous suprapubic cystostomy (SPC) should be performed under ultrasound guidance or local anesthesia.
3. Assessment: Rule out acute prostatitis, evaluate for urethral stricture, and monitor the patient for post-obstructive diuresis and electrolyte derangements if the drained residual volume exceeds 1000 mL.

Definitive Management: Initial diagnostic evaluation includes digital rectal examination (DRE), serum prostate-specific antigen (PSA), renal function tests, urine culture, and ultrasound of the KUB region (evaluating prostate volume, upper tract changes, and post-void residual volume).

1. Surgical Intervention (Gold Standard):

• Transurethral Resection of the Prostate (TURP): The standard operative intervention for symptomatic BPH with prostate volume <80 grams.
• Holmium Laser Enucleation of the Prostate (HoLEP) or Open Simple Prostatectomy (Freyer's transvesical or Millin's retropubic approach) for large glands (>80–100 grams).

2. Medical Therapy: Indicated for patients who are poor surgical candidates or during a trial without catheter (TWOC). It comprises a combination of a selective alpha-1 adrenergic blocker (Tamsulosin 0.4 mg or Silodosin 8 mg daily) for immediate symptom relief and a 5-alpha reductase inhibitor (Finasteride 5 mg or Dutasteride 0.5 mg daily) to reduce prostate volume over 6 months.

---

Emergency Management of Shock with Retained Placenta and Previous Scar

A 35-year-old multigravida presenting in shock post-home delivery with a retained placenta and a previous LSCS scar must be managed as an obstetric catastrophe—primary suspects being severe postpartum hemorrhage (PPH), morbidly adherent placenta (Placenta Accreta spectrum), or uterine rupture along the scar.

Resuscitation (Immediate ABC Approach):

1. Airway and Breathing: Administer high-flow supplemental oxygen (10–15 L/min via non-rebreather mask).
2. Circulation: Establish two wide-bore (14G or 16G) peripheral intravenous lines. Rapidly infuse warm crystalloids (Ringer's Lactate).
3. Blood Transfusion: Send blood immediately for grouping, cross-matching (at least 4 units of packed red blood cells, fresh frozen plasma, and platelets), complete blood count, and coagulation profile. Activate the hospital's Massive Transfusion Protocol (MTP).
4. Catheterization: Insert an indwelling Foley catheter to monitor hourly urine output (targeting >30 mL/hr) and decompress the bladder.

Targeted Operative and Medical Management:

1. Uterotonic Therapy: Administer intravenous oxytocin infusion (20–40 IU in 500 mL normal saline) and intramuscular Carboprost/Misoprostol sublingually, monitoring hemodynamics.
2. Examination Under Anesthesia (EUA): Transfer immediately to the operating theatre. Under general anesthesia, perform gentle manual removal of the placenta (MROP).
3. Evaluation for Scar Rupture and Placenta Accreta: Following placental removal, explore the uterine cavity digitally to assess the integrity of the previous LSCS scar. Transabdominal/transvaginal ultrasound can confirm complete evacuation and exclude intra-abdominal fluid.
4. Laparotomy: If the placenta fails to separate (Placenta Accreta/Increta) or if a uterine rupture is palpated with ongoing internal hemorrhage, perform an immediate emergency exploratory laparotomy. Repair the uterine rupture if viable, or proceed to an emergency obstetric hysterectomy if bleeding is uncontrollable or extensive placental invasion is present.
5. Postoperative Care: Administer broad-spectrum intravenous antibiotics (e.g., Ceftriaxone, Metronidazole), correct coagulopathy, and transfer to the Intensive Care Unit.

---

Contraindications to OCPs and Failure of Sterilization

Contraindications to Combined Oral Contraceptive Pills (WHO MEC Category 4):

1. Age ≥35 years who smoke ≥15 cigarettes per day.
2. Current or past history of deep vein thrombosis, pulmonary embolism, or known thrombogenic mutations (e.g., Factor V Leiden).
3. Ischemic heart disease, stroke, or complicated valvular heart disease (e.g., pulmonary hypertension).
4. Migraine with aura at any age.
5. Severe hypertension (systolic ≥160 mmHg or diastolic ≥100 mmHg) or vascular disease.
6. Current or past history of breast cancer.
7. Active liver disease: acute viral hepatitis, decompensated cirrhosis, or benign/malignant liver tumors.
8. Lactation within the first 6 weeks postpartum (estrogen impairs lactation and increases thromboembolic risk).

Causes for Failure of Sterilization:

Female Sterilization (Tubal Ligation):

1. Spontaneous recanalization of the fallopian tubes via epithelialized fistulous tracts.
2. Uteroperitoneal or tuboperitoneal fistula formation.
3. Surgical technical error: Misidentification and ligation of adjacent structures (round ligament, ovarian ligament, or epiploic appendices) instead of the fallopian tube.
4. Incomplete tubal occlusion or slippage/misplacement of Hulka clips or Falope rings.
5. Luteal phase pregnancy (fertilization having occurred immediately prior to the procedure).

Male Sterilization (Vasectomy):

1. Spontaneous recanalization/reanastomosis of the transected ends of the vas deferens.
2. Technical surgical error: Incomplete transection, failure to excise a segment, or ligation of adjacent fascial/vascular structures instead of the vas deferens.
3. Unprotected intercourse before achieving complete azoospermia (failure to comply with barrier contraception for 3 months or 20 ejaculations post-procedure).
4. Congenital duplication of the vas deferens (rare anatomical variant missed during surgery).

---

National Guidelines on Infant and Young Child Feeding (IYCF)

The Ministry of Health and Family Welfare (MoHFW), in collaboration with the Indian Academy of Pediatrics (IAP) and National Neonatal Forum (NNF), outlines standard IYCF guidelines:

1. Early Initiation: Initiation of breastfeeding within the first hour of life ("the golden hour"), ensuring skin-to-skin contact and administration of colostrum, avoiding all pre-lacteal feeds (such as honey, animal milk, or ghutti).
2. Exclusive Breastfeeding: Exclusive breastfeeding for the first six completed months (180 days) of life. No water, fluids, or other foods should be administered except oral rehydration solution, drops/syrups of vitamins, minerals, and medicines.
3. Timely Complementary Feeding: Introduction of nutritionally adequate, safe, hygienically prepared, and age-appropriate complementary foods starting at 6 months of age.
4. Continued Breastfeeding: Continued frequent, on-demand breastfeeding up to 2 years of age or beyond alongside complementary feeding.
5. Active and Responsive Feeding: Feeding young infants directly and assisting older children, adhering to food hygiene and responsive feeding principles during illness and convalescence.

Goals of the Guidelines:

1. Reduction of Neonatal, Infant, and Under-5 Mortality Rates (IMR and U5MR) by protecting against severe infections (diarrhea and pneumonia).
2. Prevention of Childhood Undernutrition: Directly tackling and reducing the prevalence of stunting, wasting, and underweight in children under 5 years, aligning with POSHAN Abhiyaan and Sustainable Development Goal 2 (Zero Hunger).
3. Optimal Neurodevelopment: Fostering early brain architecture and cognitive development through essential fatty acids and maternal-infant bonding.
4. Institutional Targets: Achieving >90% institutional adherence to early initiation of breastfeeding and raising exclusive breastfeeding rates across all demographics.